Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Abrysvo study in children at high risk of RSV disease
2026-525797-19-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Oct 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Abrysvo with Placebo (2 arms). Planned start Oct 2026; status: authorised.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2026-525797-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525797-19-00.